Associations of Maternal Use of Benzodiazepines or Benzodiazepine-like Hypnotics During Pregnancy With Immediate Pregnancy Outcomes in Norway

Abstract

IMPORTANCE Understanding the safety profile of medications used in pregnancy is crucial for clinical decision-making. Few studies exist on the associations of exposure to benzodiazepines and benzodiazepine-like hypnotic drugs (z-hypnotics) in pregnancy with pregnancy outcomes. OBJECTIVE To determine whether exposure to benzodiazepines or z-hypnotics in pregnancy is associated with greater risk of negative immediate pregnancy outcomes compared with nonexposure. DESIGN, SETTING, AND PARTICIPANTS This questionnaire-based cohort study used data from the Norwegian Mother, Father and Child cohort study (MoBa), which also includes data from the Medical Birth Registry of Norway. Pregnant women were recruited from all over Norway from 1999 and 2008. The first child was born in October 1999 and the last in July 2009. This analysis included women who completed 3 questionnaires, twice during pregnancy and once 6 months after delivery. Data analyses were conducted from September to November 2019. EXPOSURES Self-reported exposure to benzodiazepines or z-hypnotics during pregnancy, characterized in terms of any exposure, timing (ie, early, middle, or late), and duration of exposure. MAIN OUTCOMES AND MEASURES The main outcomes were gestational age at delivery, risk of preterm delivery, birth weight, birth weight relative to gestational age and sex, risk of being small for gestational age, head circumference, Apgar score less than 7 at 5 minutes, and risk of neonatal respiratory distress. Continuous outcomes are reported using effect estimates as mean differences, and binary outcomes are reported using risk ratios. RESULTS The MoBa study included 114 234 mother-child dyads. This analysis of MoBa data includes 82 038 singleton pregnancies among 69 434 unique women. Mean (SD) maternal age was 30.2 (4.5) years, and 37 641 pregnancies (45.9%) were in primiparous women. Exposure to benzodiazepines or z-hypnotics was reported in 679 pregnancies (0.8%). After adjusting for all measured baseline and postbaseline confounders, benzodiazepine or z-hypnotic use during pregnancy was associated with lower birth weight (mean difference, −79.3 [95% CI, −126.7 to −31.9] g), lower gestational age at birth (mean difference, −2.1 [95% CI, −3.3 to −0.9] days), and higher risk of preterm birth (risk ratio, 1.41 [95% CI, 1.03 to 1.94]). We found no significant association of exposure to benzodiazepines or z-hypnotics with the child's birth weight relative to gestational age and sex (z score), or any of the other immediate birth outcomes. CONCLUSIONS AND RELEVANCE These findings suggest that the magnitude of the association of exposure to benzodiazepines or z-hypnotics with gestational age is not necessarily clinically significant. The absence of an association of exposure to benzodiazepines or z-hypnotics with z score for birth weight relative to gestational age and sex suggests that association of exposure to (continued) Key Points Question Is there an association of prenatal exposure to benzodiazepines or benzodiazepine-like hypnotics with immediate...

Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice

“…In a Norwegian questionnaire cohort study of 82,030 singleton pregnancies among 69,434 women (mean age 30 years), lower gestational age at birth and higher risk of preterm birth were associated with prenatal use of benzodiazepines or z-drugs [159]. Similarly, after adjusting for publication bias, a systematic review and meta-analysis of 14 studies found significant associations of benzodiazepine use during pregnancy and both gestational age and small for gestational age; an association with neonatal intensive care unit (NICU) admission (OR 2.61) was clinically relevant as well as statistically significant [160].…”

Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force “Sleep and Women,” the Italian Marcè Society and international experts task force for perinatal mental health

“…Benzodiazepines and benzodiazepine-related drugs during pregnancy pass through the placenta, with a greater placental transfer in late pregnancy, compared to early pregnancy (Chaudhry and Susser 2018;Bei and Coo 2015). As reviewed from Bei and Coo 2015), the use of these drugs has been associated with a range of adverse birth outcomes including higher risk of spontaneous abortion (odds ratio (OR) 2.39, 95% confidence interval (CI) 2.10-2.73) (Sheehy et al 2019) and preterm birth (OR 2.03, 95% CI 1.11-3.69) (Ogawa et al 2018;Chaudhry and Susser 2018;Huitfeldt et al 2020). Maternal use of benzodiazepines drugs in the third trimester has been associated with floppy infant syndrome, including symptoms of hypothermia, lethargy, and respiratory problems (Bulletins-Obstetrics 2008), and withdrawal symptoms which may persist for several months in the neonate (Bulletins-Obstetrics 2008).…”

Sleep disorders in pregnancy

“…Their use in pregnancy is limited due to potential teratogenicity, and fetal withdrawal symptoms. HUITFELDT et al [50] reviewed data from a large population-based cohort study of 114 234 pregnancies and found the exposure of these drugs were associated with lower birth weight, lower gestational age at delivery and higher risk of pre-term delivery.…”